Adrenoleukodystrophy laboratory findings
|
Adrenoleukodystrophy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Adrenoleukodystrophy laboratory findings On the Web |
|
American Roentgen Ray Society Images of Adrenoleukodystrophy laboratory findings |
|
Risk calculators and risk factors for Adrenoleukodystrophy laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
An elevated concentration of plasma levels of VLCFA suggests the presence of Adrenoleukodystrophy.DNA-based diagnosis can be obtained to look for mutations in the ABCD1 gene in the case of carriers and is particularly important in the diagnosis of the disease in women.
Laboratory Findings
Plasma VLCFA Assay
- The diagnosis is established by clinical findings and the detection of serum long chain fatty acid levels.[1]
DNA-based Diagnosis
- Chromosome study to look for changes (mutations) in the ABCD1 gene. It is particularly reliable in carriers[2] and recommended as the diagnostic assay in women.
Histopathology: Adrenoleukodystrophy of Brain
{{#ev:youtube|bv_Ra5pxPRI}}
References
- ↑ Moser AB, Kreiter N, Bezman L, Lu S, Raymond GV, Naidu S; et al. (1999). "Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls". Ann Neurol. 45 (1): 100–10. doi:10.1002/1531-8249(199901)45:1<100::aid-art16>3.0.co;2-u. PMID 9894883.
- ↑ Boehm CD, Cutting GR, Lachtermacher MB, Moser HW, Chong SS (1999). "Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy". Mol Genet Metab. 66 (2): 128–36. doi:10.1006/mgme.1998.2779. PMID 10068516.